← Search & browse all drugs
NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Dopa and dopa derivatives
etilevodopa and decarboxylase inhibitor
N04BA06
Forms & Strengths
- Tablets: 100mg etilevodopa + 10mg carbidopa
- Tablets: 200mg etilevodopa + 50mg carbidopa
- Capsules: 50mg etilevodopa + 12.5mg carbidopa
Adult Dosing
- Initial dose: 100mg etilevodopa + 10mg carbidopa tid
- Maintenance dose: 200mg etilevodopa + 50mg carbidopa tid/qid
- Max dose: 1000mg etilevodopa + 250mg carbidopa per day
Pediatric Dosing
- Not established for children under 12 years
- 12-15 years: 100mg etilevodopa + 10mg carbidopa tid, adjust according to response
Indications
- Idiopathic Parkinson's disease
- Post-encephalitic parkinsonism
- Symptomatic parkinsonism
Mechanism of Action
- Etilevodopa: precursor to dopamine, increasing dopaminergic activity
- Decarboxylase inhibitor (carbidopa): prevents peripheral conversion of etilevodopa to dopamine, increasing availability in CNS
Contraindications
- Hypersensitivity to etilevodopa, carbidopa, or other dopa-decarboxylase inhibitors
- Narrow-angle glaucoma
- Melanoma
Adverse Reactions
- Nausea
- Vomiting
- Dyskinesia
- Hallucinations
- Orthostatic hypotension
Drug Interactions
- MAOIs: may increase risk of hypertensive crisis
- Tricyclic antidepressants: may increase risk of dyskinesia
- Antipsychotics: may decrease efficacy of etilevodopa
Curated Content: Needs Vetting Before Put to Clinical Use